Fundraising FoxAbata Therapeutics
Cambridge, US · 3 known investors
Find your way into Abata Therapeutics
Sign up to see every warm intro you have to Abata Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Abata Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investors · 3
Lightspeed Venture Partnerslisted by Lightspeed Venture PartnersMenlo Park · $1M – $5M
How we know: Lightspeed Venture Partners's portfolio page · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Third Rock VenturesreportedBoston · $100K – $5M
How we know: a partner's Signal profile · board seat on SEC Form D · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$60.3M disclosed across 2 rounds · 2021–2023
▶$15.3MraisedDec 2023 · 8 investors · BiotechnologyRule 506(b)
▶$15.3MraisedDec 2023 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SAMANTHA SINGERExecutive Officer, Director
- LEONARD DRAGONEExecutive Officer
- VALERIE ODEGARDDirector
- STEPHEN SOFENExecutive Officer
- SANDY LAZZARIExecutive Officer
- SHELLEY CHUDirector
- NAGESH MAHANTHAPPADirector
- JOHN TRZUPEKExecutive Officer
- ABBIE CELNIKERDirector
- MITCH FINERDirector
- DAVID KAUFMANDirector
- LORENCE KIMDirector
- ELLEN CAHIR-MCFARLANDExecutive Officer
- Amount sold
- $15.3M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$45MraisedJun 2022 · 7 investors · BiotechnologyRule 506(b)
▶$45MraisedJun 2022 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- SAMANTHA SINGERExecutive Officer, Director
- ABBIE CELNIKERDirector
- MITCH FINERDirector
- NAGESH MAHANTHAPPADirector
- LORENCE KIMDirector
- SANDY LAZZARIExecutive Officer
- SHELLEY CHUDirector
- STEPHEN SOFENExecutive Officer
- VALERIE ODEGARDDirector
- JOHN TRZUPEKExecutive Officer
- Offering amount
- $95M
- Amount sold
- $45M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Abata Therapeutics's investors?
- Abata Therapeutics's investors include Lightspeed Venture Partners, Ascenta Capital, Third Rock Ventures.
- How much funding has Abata Therapeutics raised?
- Abata Therapeutics has disclosed $60.3M raised across 2 rounds.
- Where is Abata Therapeutics headquartered?
- Abata Therapeutics is headquartered in Cambridge, US.